The Long Noncoding RNA Cancer Susceptibility 9 and RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein L Form a Complex and Coregulate Genes Linked to AKT Signaling
Overview
Authors
Affiliations
The identification of viability-associated long noncoding RNAs (lncRNAs) might be a promising rationale for new therapeutic approaches in liver cancer. Here, we applied an RNA interference screening approach in hepatocellular carcinoma (HCC) cell lines to find viability-associated lncRNAs. Among the multiple identified lncRNAs with a significant impact on HCC cell viability, we selected cancer susceptibility 9 (CASC9) due to the strength of its phenotype, expression, and up-regulation in HCC versus normal liver. CASC9 regulated viability across multiple HCC cell lines as shown by clustered regularly interspaced short palindromic repeats interference and single small interfering RNA (siRNA)-mediated and siRNA pool-mediated depletion of CASC9. Further, CASC9 depletion caused an increase in apoptosis and a decrease of proliferation. We identified the RNA binding protein heterogeneous nuclear ribonucleoprotein L (HNRNPL) as a CASC9 interacting protein by RNA affinity purification and validated it by native RNA immunoprecipitation. Knockdown of HNRNPL mimicked the loss-of-viability phenotype observed upon CASC9 depletion. Analysis of the proteome (stable isotope labeling with amino acids in cell culture) of CASC9-depleted and HNRNPL-depleted cells revealed a set of coregulated genes which implied a role of the CASC9:HNRNPL complex in AKT signaling and DNA damage sensing. CASC9 expression levels were elevated in patient-derived tumor samples compared to normal control tissue and had a significant association with overall survival of HCC patients. In a xenograft chicken chorioallantoic membrane model, we measured decreased tumor size after knockdown of CASC9. Conclusion: Taken together, we provide a comprehensive list of viability-associated lncRNAs in HCC; we identified the CASC9:HNRNPL complex as a clinically relevant viability-associated lncRNA/protein complex which affects AKT signaling and DNA damage sensing in HCC.
Awadh A, Alharthi A, Alghamdi B, Alghamdi S, Baqays M, Binrabaa I J Glob Infect Dis. 2025; 16(4):127-134.
PMID: 39886088 PMC: 11775402. DOI: 10.4103/jgid.jgid_211_23.
Kim Y, Ha H, Kim K Genes Genomics. 2024; 46(9):1085-1095.
PMID: 39112833 DOI: 10.1007/s13258-024-01549-z.
approaches for drug repurposing in oncology: a scoping review.
Cavalcante B, Freitas R, Siquara da Rocha L, Santos R, Souza B, Ramos P Front Pharmacol. 2024; 15:1400029.
PMID: 38919258 PMC: 11196849. DOI: 10.3389/fphar.2024.1400029.
Wassmer E, Koppany G, Hermes M, Diederichs S, Caudron-Herger M Nucleic Acids Res. 2024; 52(13):7504-7522.
PMID: 38917322 PMC: 11260472. DOI: 10.1093/nar/gkae536.
Conserved role of hnRNPL in alternative splicing of epigenetic modifiers enables B cell activation.
Subramani P, Fraszczak J, Helness A, Estall J, Moroy T, Di Noia J EMBO Rep. 2024; 25(6):2662-2697.
PMID: 38744970 PMC: 11169469. DOI: 10.1038/s44319-024-00152-3.